The Health subcommittee of the Energy & Commerce Committee took key steps this week on H.R.1192 – The National Diabetes Clinical Care Commission Act. They marked it up and sent it to the full committee for consideration.
The bill seeks to coordinate the federal response to diabetes through a limited time commission. This commission is an approach that proved successful a generation ago, leading to trials that proved the value of tight control. Advances in diabetes medications and devices are an opportunity to be successful coordinating innovative diabetes care again.
This is progress. Currently, a bipartisan majority of the House has cosponsored the bill. Now is the time to ask for action.